Phase IIb Genesis Study

Princeton, New Jersey – Apr. 18, 2018 - Origin, Inc., a Phase IIb clinical-stage biotechnology company, today announced that the US Food and Drug Administration has approved its request to conclude patient recruitment in the “GENESIS” dose-ranging (Phase IIb) trial of plasma generated nitric oxide in patients with chronic diabetic foot ulcers (DFUs). The request to conclude the trial follows positive interim analysis and evidence of healing in chronic DFUs, with 83 patients randomized.

For more information, please download the Press Release.

Philip Andrews